Takeda strengthens patient offering in India via availability of Vedolizumab (Kynteles®)
Introduces innovative Gastrointestinal portfolio for patients with Inflammatory Bowel Diseases (IBD) and Ulcerative Colitis and Crohn’s Disease Kynteles® is likely to benefit patients with a low risk of serious or opportunistic infections like Tuberculosis3 Current…









